714 related articles for article (PubMed ID: 32699351)
21. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
22. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
[TBL] [Abstract][Full Text] [Related]
23. Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.
Pistoia V; Tumino N; Vacca P; Veneziani I; Moretta A; Locatelli F; Moretta L
Front Immunol; 2018; 9():984. PubMed ID: 29867961
[TBL] [Abstract][Full Text] [Related]
24. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
25. Gamma-delta (γδ) T cells: friend or foe in cancer development?
Zhao Y; Niu C; Cui J
J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
[TBL] [Abstract][Full Text] [Related]
26. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.
Brandes M; Willimann K; Bioley G; Lévy N; Eberl M; Luo M; Tampé R; Lévy F; Romero P; Moser B
Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2307-12. PubMed ID: 19171897
[TBL] [Abstract][Full Text] [Related]
27. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
Knight A; Mackinnon S; Lowdell MW
Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
[TBL] [Abstract][Full Text] [Related]
28. Working in "NK Mode": Natural Killer Group 2 Member D and Natural Cytotoxicity Receptors in Stress-Surveillance by γδ T Cells.
Silva-Santos B; Strid J
Front Immunol; 2018; 9():851. PubMed ID: 29740448
[TBL] [Abstract][Full Text] [Related]
29. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
30. Role of gammadelta T lymphocytes in tumor defense.
Zocchi MR; Poggi A
Front Biosci; 2004 Sep; 9():2588-604. PubMed ID: 15358583
[TBL] [Abstract][Full Text] [Related]
31. Intrahepatic CD69
Bruni E; Cimino MM; Donadon M; Carriero R; Terzoli S; Piazza R; Ravens S; Prinz I; Cazzetta V; Marzano P; Kunderfranco P; Peano C; Soldani C; Franceschini B; Colombo FS; Garlanda C; Mantovani A; Torzilli G; Mikulak J; Mavilio D
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863820
[TBL] [Abstract][Full Text] [Related]
32. Gamma/delta T cells as cellular vehicles for anti-tumor immunity.
Wang CQ; Lim PY; Tan AH
Front Immunol; 2023; 14():1282758. PubMed ID: 38274800
[TBL] [Abstract][Full Text] [Related]
33. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
Rei M; Pennington DJ; Silva-Santos B
Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
[TBL] [Abstract][Full Text] [Related]
34. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
[TBL] [Abstract][Full Text] [Related]
35. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
[TBL] [Abstract][Full Text] [Related]
36. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
37. Function of γδ T cells in tumor immunology and their application to cancer therapy.
Park JH; Lee HK
Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic avenues for γδ T cells in cancer.
Costa GP; Mensurado S; Silva-Santos B
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007241
[TBL] [Abstract][Full Text] [Related]
39. γδ T-cell immunotherapy for lung cancer.
Yoshida Y; Nakajima J; Wada H; Kakimi K
Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
[TBL] [Abstract][Full Text] [Related]
40. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.
Maeurer MJ; Martin D; Walter W; Liu K; Zitvogel L; Halusczcak K; Rabinowich H; Duquesnoy R; Storkus W; Lotze MT
J Exp Med; 1996 Apr; 183(4):1681-96. PubMed ID: 8666926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
